Teva Pharmaceutical Industries Ltd (TEVA)

TEVA (NYSE:Drugs) EQUITY
$51.87
pos +0.21
+0.41%
Today's Range: 51.09 - 51.97 | TEVA Avg Daily Volume: 6,484,700
Last Update: 05/31/16 - 4:04 PM EDT
Volume: 4,981,627
YTD Performance: -21.30%
Open: $51.09
Previous Close: $51.66
52 Week Range: $49.51 - $72.31
Oustanding Shares: 914,000,000
Market Cap: 47,217,240,000
6-Month Chart
TheStreet Ratings Grade for TEVA
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 12 12
Moderate Buy 2 2 2 2
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.53 1.53 1.53
Latest Dividend: 0.29
Latest Dividend Yield: 2.24%
Dividend Ex-Date: 05/20/16
Price Earnings Ratio: 28.38
Price Earnings Comparisons:
TEVA Sector Avg. S&P 500
28.38 26.90 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-9.34% -14.89% 31.32%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 0.00 -0.01
Net Income -47.50 -0.20 -0.06
EPS -48.90 -0.20 -0.06
Earnings for TEVA:
EBITDA 5.79B
Revenue 19.65B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.16 $1.38 $5.12 $5.63
Number of Analysts 5 5 7 8
High Estimate $1.19 $1.44 $5.32 $6.06
Low Estimate $1.14 $1.30 $4.64 $4.63
Prior Year $1.43 $1.35 $5.42 $5.12
Growth Rate (Year over Year) -18.60% 2.37% -5.61% 10.08%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Allergan and retailers are just a couple of examples.
We expect an upward revision in AGN's valuation multiple after the generics deal with Teva.
Allergan's stock may start to realize the potential already seen by several Real Money analysts and contributors.
Problems with mesh products and high leverage might scare away a potential buyer. 
Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.
The company hit all the major points of investor concern.

Biotech Gets a Lifeline Real Money Pro($)

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
If TEVA breaks below $50, then a longer-term decline could be in the cards.
This year's mix of Sohn speakers includes asset managers, a behavioral economist and two-time Super Bowl champ Eli Manning.
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.

Columnist Conversations

The Fed has been talkative lately about the 'strength' in the economy with a 2% rate of growth. Certainly tha...
Market flat as we hit the noon hour. Oil tries once again to scale the $50 level. Biotech goes for three wee...
I would think he sees the boatload of cash coming to AGN if/when they close the TEVA deal for their generics. ...
Looking like a slightly up start to the holiday shortened trading week as consumer spending posts its best gai...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.